Department of Pharmacy, King Hussein Cancer Center, Amman, Jordan.
Sultan Qaboos Univ Med J. 2024 Aug;24(3):354-359. doi: 10.18295/squmj.6.2024.029. Epub 2024 Aug 29.
Albumin is commonly used for various indications; however, there is conflicting data regarding its appropriate use in different clinical cases. This study aimed to determine the pattern and appropriateness of albumin use among cancer patients at the King Hussein Cancer Center in Jordan.
A retrospective analysis was conducted on adult cancer patients who were prescribed albumin between January 2019 and July 2020 in both outpatient and inpatient settings. Data collected included demographics, prescribing services, indications and dosing regimens. A literature review was performed using PubMed to assess the appropriateness of albumin indications and dosing regimens against current guidelines, drug information resources and the package insert.
Albumin was prescribed to 1,361 patients during the study period. Each patient received an average of 74.4 ± 89 g of albumin for an average of 2.6 ± 1.8 days. Albumin use was deemed appropriate in 69% of the patients. The critical care service accounted for the highest albumin consumption, with 37% of prescriptions for septic shock. Inappropriate use of albumin was most prevalent in the medical solid tumour services (40.8% of prescriptions), primarily for edema (28%).
To the best of the author's knowledge, this study is the first to evaluate albumin use in a large cohort of oncology patients. Approximately one-third of the albumin prescriptions were considered inappropriate. Continuous education on appropriate usage and regular evaluations of guideline adherence are essential to ensure proper utilisation of albumin in cancer care.
白蛋白被广泛用于多种适应证；然而，其在不同临床情况下的合理应用存在相互矛盾的数据。本研究旨在确定在约旦侯赛因国王癌症中心的癌症患者中白蛋白的使用模式和合理性。
对 2019 年 1 月至 2020 年 7 月间在门诊和住院环境中开具白蛋白处方的成年癌症患者进行回顾性分析。收集的数据包括人口统计学、开具处方服务、适应证和剂量方案。使用 PubMed 进行文献回顾，以评估白蛋白适应证和剂量方案与现行指南、药物信息资源和说明书的相符性。
在研究期间，白蛋白被开具给 1361 名患者。每位患者平均接受 74.4 ± 89 g 白蛋白，平均使用 2.6 ± 1.8 天。69%的患者认为白蛋白的使用是合理的。重症监护服务的白蛋白消耗量最高，其中 37%的处方用于脓毒性休克。在医学实体瘤服务中（40.8%的处方），白蛋白的不适当使用最为普遍，主要用于水肿（28%）。
据作者所知，这是首次在大型癌症患者队列中评估白蛋白使用情况的研究。约三分之一的白蛋白处方被认为是不合理的。持续进行关于合理使用的教育以及定期评估对指南的遵守情况对于确保白蛋白在癌症治疗中的合理应用至关重要。
